Recent Developments in the Management of Advanced Prostate Cancer

被引：2
作者：
Srinivas, Sandy [1 ]
机构：
[1] Stanford Canc Inst, 875 Blake Wilbur Dr, Stanford, CA 94305 USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2020年 / 18卷 / 07期
关键词：
THERAPY;
D O I：
10.6004/jnccn.2020.5021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Numerous new options are available for the treatment of prostate cancer when it progresses beyond localized disease. Older drugs, first developed for treatment of metastatic castration-resistant prostate cancer (CRPC), are being used to treat nonmetastatic disease based on results of large randomized controlled trials. Sequencing of available treatment options is challenging for CRPC, but there is some guidance from trial data. Cross-resistance among newer hormonal drugs is a concern, and therefore switching to another class of drug is preferred. Emerging treatments on the horizon, such as PARP inhibitors in patients with BRCA2 mutations and lutetium-177 in those with prostate-specific membrane antigen (PSMA)-positive disease, may look promising to improve outcomes among those with advanced prostate cancer.
引用
收藏
页码：969 / 972
页数：4
相关论文
共 14 条
  • [1] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Armstrong, Andrew J.
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +
  • [2] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) : 13 - 24
  • [3] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
    Davis, Ian D.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, T. Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Sweeney, Christopher J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) : 121 - 131
  • [4] Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
    de Wit, Ronald
    de Bono, Johann
    Sternberg, Cora N.
    Fizazi, Karim
    Tombal, Bertrand
    Wuelfing, Christian
    Kramer, Gero
    Eymard, Jean-Christophe
    Bamias, Aristotelis
    Carles, Joan
    Iacovelli, Roberto
    Melichar, Bohuslav
    Sverrisdottir, Asgerdur
    Theodore, Christine
    Feyerabend, Susan
    Helissey, Carole
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Castellano, Daniel
    de Wit, Ronald
    de Bono, Johann
    Sternberg, Cora N.
    Fizazi, Karim
    Tombal, Bertrand
    Wulfing, Christian
    Kramer, Gero
    Eymard, Jean-Christophe
    Bamias, Aristotelis
    Carles, Joan
    Iacovelli, Roberto
    Melichar, Bohuslav
    Sverrisdottir, Asgerour
    Theodore, Christine
    Feyerabend, Susan
    Helissey, Carole
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Castellano, Daniel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (26) : 2506 - 2518
  • [5] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    Sulur, Giri
    Luna, Yesenia
    Li, Susan
    Mundle, Suneel
    Chi, Kim N.
    [J]. LANCET ONCOLOGY, 2019, 20 (05) : 686 - 700
  • [6] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13) : 1235 - 1246
  • [7] Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
    Gravis, Gwenaelle
    Fizazi, Karim
    Joly, Florence
    Oudard, Stephane
    Priou, Franck
    Esterni, Benjamin
    Latorzeff, Igor
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Rolland, Frederic
    Theodore, Christine
    Deplanque, Gael
    Ferrero, Jean Marc
    Pouessel, Damien
    Mourey, Loic
    Beuzeboc, Philippe
    Zanetta, Sylvie
    Habibian, Muriel
    Berdah, Jean Francois
    Dauba, Jerome
    Baciuchka, Marjorie
    Platini, Christian
    Linassier, Claude
    Labourey, Jean Luc
    Machiels, Jean Pascal
    El Kouri, Claude
    Ravaud, Alain
    Suc, Etienne
    Eymard, Jean Christophe
    Hasbini, Ali
    Bousquet, Guilhem
    Soulie, Michel
    [J]. LANCET ONCOLOGY, 2013, 14 (02) : 149 - 158
  • [8] [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
    Hofman, Michael S.
    Violet, John
    Hicks, Rodney J.
    Ferdinandus, Justin
    Thang, Sue Ping
    Akhurst, Tim
    Iravani, Amir
    Kong, Grace
    Kumar, Aravind Ravi
    Murphy, Declan G.
    Eu, Peter
    Jackson, Price
    Scalzo, Mark
    Williams, Scott G.
    Sandhu, Shahneen
    [J]. LANCET ONCOLOGY, 2018, 19 (06) : 825 - 833
  • [9] Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
    Hussain, Maha
    Fizazi, Karim
    Saad, Fred
    Rathenborg, Per
    Shore, Neal
    Ferreira, Ubirajara
    Ivashchenko, Petro
    Demirhan, Eren
    Modelska, Katharina
    Phung, De
    Krivoshik, Andrew
    Sternberg, Cora N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) : 2465 - 2474
  • [10] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
    James, Nicholas D.
    Sydes, Matthew R.
    Clarke, Noel W.
    Mason, Malcolm D.
    Dearnaley, David P.
    Spears, Melissa R.
    Ritchie, Alastair W. S.
    Parker, Christopher C.
    Russell, J. Martin
    Attard, Gerhardt
    de Bono, Johann
    Cross, William
    Jones, Rob J.
    Thalmann, George
    Amos, Claire
    Matheson, David
    Millman, Robin
    Alzouebi, Mymoona
    Beesley, Sharon
    Birtle, Alison J.
    Brock, Susannah
    Cathomas, Richard
    Chakraborti, Prabir
    Chowdhury, Simon
    Cook, Audrey
    Elliott, Tony
    Gale, Joanna
    Gibbs, Stephanie
    Graham, John D.
    Hetherington, John
    Hughes, Robert
    Laing, Robert
    McKinna, Fiona
    McLaren, Duncan B.
    O'Sullivan, Joe M.
    Parikh, Omi
    Peedell, Clive
    Protheroe, Andrew
    Robinson, Angus J.
    Srihari, Narayanan
    Srinivasan, Rajaguru
    Staffurth, John
    Sundar, Santhanam
    Tolan, Shaun
    Tsang, David
    Wagstaff, John
    Parmar, Mahesh K. B.
    [J]. LANCET, 2016, 387 (10024) : 1163 - 1177
12